Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care Settings

Completed

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: afatinib

First Posted Date: 2015-05-12

Last Posted Date: 2022-04-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 80

Registration Number: NCT02440854

Locations: 🇬🇷
Interbalkan Medical Center of Thessaloniki, Thessaloniki, Greece
🇬🇷
Chest Hospital of Athens "Sotiria", Athens, Greece
🇬🇷
University General Hospital of Heraklion, Heraklion, Greece

and more 4 locations

BI 409306 Cardiac Safety Trial in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: BI 409306

First Posted Date: 2015-05-08

Last Posted Date: 2024-10-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT02438683

Locations: 🇩🇪
1289.28.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Relative Bioavailability of Two Newly Developed Tablet Formulations (TF2 and iFF)Compared to BI 1060469 TF1 Formulation, Following Oral Administration (Low and High Dose)in Healthy Female Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 1060469, TF1, Reference
Drug: BI 1060469, TF2, Test
Drug: BI 1060469, iFF, Test

First Posted Date: 2015-05-08

Last Posted Date: 2015-09-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 29

Registration Number: NCT02438696

Locations: 🇩🇪
1333.4.1 Boehringer Ingelheim Investigational Site, Biberach, Germany

Evaluation the Effectiveness of the Risk Minimisation Activities in the Treatment of Stroke Prevention in Atrial Fibrillation

Completed

Conditions: Atrial Fibrillation

First Posted Date: 2015-05-05

Last Posted Date: 2016-09-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 1213

Registration Number: NCT02433366

Locations: 🇨🇿
Boehringer Ingelheim Investigational Site 113, Sternberk, Czech Republic
🇫🇷
Boehringer Ingelheim Investigational Site 29, Besançon, France
🇫🇷
Boehringer Ingelheim Investigational Site 35, Eckwersheim, France

and more 158 locations

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fasted Male.

Phase 1

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: tamsulosin HCl
Drug: tamsulosin capsules

First Posted Date: 2015-04-16

Last Posted Date: 2020-04-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02417831

Determine the Bioequivalence of Two Formulations of Tamsulosin HCl Capsules in Fed Male.

Phase 1

Completed

Conditions: Prostatic Hyperplasia

Interventions: Drug: tamsulosin (Astellas)
Drug: Tamsulosin HCL

First Posted Date: 2015-04-16

Last Posted Date: 2020-04-17

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 34

Registration Number: NCT02417844

BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma

Phase 3

Terminated

Conditions: Lymphoma, Non-Hodgkin

Interventions: Drug: BI 695500
Drug: Rituximab

First Posted Date: 2015-04-15

Last Posted Date: 2017-01-30

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 2

Registration Number: NCT02417129

Locations: 🇨🇿
Boehringer Ingelheim Investigational Site, Praha, Czech Republic

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 1

Interventions: Drug: Empagliflozin
Drug: Placebo

First Posted Date: 2015-04-13

Last Posted Date: 2019-01-03

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 730

Registration Number: NCT02414958

Locations: 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸
Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States
🇺🇸
Office of Dr. Michelle Zaniewski-Singh, Houston, Texas, United States

and more 128 locations

Study of Systemic and Ocular Safety and Pharmacokinetics of BI 409306 in Patients With Schizophrenia, Alzheimer's Disease, and Healthy Volunteers

Phase 1

Completed

Conditions: Schizophrenia
Alzheimer Disease

Interventions: Drug: Placebo matching BI 409306 25 mg
Drug: Placebo matching BI 409306 50 mg
Drug: BI 409306 25 mg
Drug: BI 409306 50 mg

First Posted Date: 2015-03-19

Last Posted Date: 2024-04-19

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 61

Registration Number: NCT02392468

Locations: 🇺🇸
Memory Enhancement Center of America, Inc., Eatontown, New Jersey, United States
🇺🇸
Community Clinical Research, Inc., Austin, Texas, United States
🇺🇸
University of California San Diego, La Jolla, California, United States

VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: treatment

First Posted Date: 2015-03-19

Last Posted Date: 2023-12-15

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 816

Registration Number: NCT02392455

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy